Organigram names former British American Tobacco executive as new CEO

Organigram Global Inc. (TSX: OGI) (NASDAQ: OGI) announced the appointment of James Yamanaka as chief executive officer, effective January 15, 2026. Yamanaka previously served as Global Head of Strategy at British American Tobacco.

Yamanaka spent more than 20 years at British American Tobacco, holding various strategy and management positions across Europe and Asia. As Area Director for North Asia, he oversaw operations in Japan and South Korea. He also led the transformation of BAT's Northern Europe operations, including the acquisition of a nicotine pouch business.

Peter Amirault, current board chairman, will serve as executive chair on an interim basis starting December 1 to oversee daily operations until Yamanaka assumes the CEO role. Geoff Machum will serve as independent lead director during this transition period.

"James' history of driving strong international growth aligns perfectly with Organigram's global aspirations," Amirault said in a statement.

Yamanaka holds degrees from UC San Diego, Georgetown University, and London Business School. He will be based in Toronto and must complete required procedures including immigration matters before assuming the role.

The company describes itself as a Canadian cannabis producer. Yamanaka will also join the company's board of directors when he becomes CEO.

You May Also Be Interested In

• Calix names Juergen Lindner as chief marketing officer
• S&P Global completes sale of energy software portfolio to SLB
• Polaryx Therapeutics names Will Charlton as chief medical officer